OKTA vs ZYME · P/E 84, rev $2.61B vs rev $76.3M
Okta Inc (OKTA) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported OKTA revenue for 2025-01-31 was $2.61B. Net income was $28.0M. Revenue was up 15.3% from 2024-01-31 to 2025-01-31. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
OKTA currently screens at market cap $20.06B and trailing P/E 83.6. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the OKTA and ZYME stock pages for the full models.
Not investment advice.